Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Urban Novak

Showing results (81-90 of 103) with videos related to

Pageof 11
Sort By:
Eclinicalmedicine|October 2, 2023
Combined therapy with ibrutinib and bortezomib followed by ibrutinib maintenance in relapsed or refractory mantle cell lymphoma and high-risk features: a phase 1/2 trial of the European MCL network (SAKK 36/13)Urban Novak, Martin Fehr, Sämi Schär, et al.
Frontiers in Immunology|October 13, 2023
Organ complications after CD19 CAR T-cell therapy for large B cell lymphoma: a retrospective study from the EBMT transplant complications and lymphoma working partyOlaf Penack, Christophe Peczynski, Christian Koenecke, et al.
Blood Advances|August 11, 2020
Prospective long-term follow-up after first-line subcutaneous cladribine in hairy cell leukemia: a SAKK trialRudolf Benz, Kornelius Arn, Martin Andres, et al.
Hematological Oncology|December 7, 2023
Hematopoietic cell transplantation and cellular therapies in Switzerland. Evolution over 25 years. A report from the stem cell transplantation and cellular therapies working groups of the SBST 1997-2021Jakob R Passweg, Helen Baldomero, Marc Ansari, et al.
Blood Advances|May 10, 2022
SAKK 35/15: a phase 1 trial of obinutuzumab in combination with venetoclax in patients with previously untreated follicular lymphomaAnastasios Stathis, Ulrich Mey, Sämi Schär, et al.
Cancer|September 25, 2014
Prognostic factors for advanced-stage human immunodeficiency virus-associated classical Hodgkin lymphoma treated with doxorubicin, bleomycin, vinblastine, and dacarbazine plus combined antiretroviral therapy: a multi-institutional retrospective studyJorge J Castillo, Mark Bower, Jérémy Brühlmann, et al.
Blood Advances|March 4, 2026
OUTCOMES OF PATIENTS OVER 70 YEARS TREATED WITH BREXU-CEL FOR R/R MANTLE CELL LYMPHOMA: A STUDY FROM THE CTIWP OF EBMTNicole Santoro, Jarl Eduard Mooyaart, Urban Novak, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 27, 2023
Differential Efficacy From the Addition of Bortezomib to R-CHOP in Diffuse Large B-Cell Lymphoma According to the Molecular Subgroup in the REMoDL-B Study With a 5-Year Follow-UpAndrew J Davies, Sharon Barrans, Louise Stanton, et al.
Blood Advances|January 30, 2025
Six-month rituximab-lenalidomide regimen in advanced untreated follicular lymphoma: SAKK 35/10 trial 10-year updateEva Kimby, Sämi Schär, Maria Cristina Pirosa, et al.
Blood Advances|March 25, 2026
Real-world experience with Tabelecleucel within and beyond the approval labelKiavasch Mohammad Nejad Farid, Florian Kocher, Tobias Arnold, et al.
Pageof 11

Showing results (81-90 of 103) with videos related to

Sort By:
Pageof 11
Eclinicalmedicine|October 2, 2023
Combined therapy with ibrutinib and bortezomib followed by ibrutinib maintenance in relapsed or refractory mantle cell lymphoma and high-risk features: a phase 1/2 trial of the European MCL network (SAKK 36/13)Urban Novak, Martin Fehr, Sämi Schär, et al.
Frontiers in Immunology|October 13, 2023
Organ complications after CD19 CAR T-cell therapy for large B cell lymphoma: a retrospective study from the EBMT transplant complications and lymphoma working partyOlaf Penack, Christophe Peczynski, Christian Koenecke, et al.
Blood Advances|August 11, 2020
Prospective long-term follow-up after first-line subcutaneous cladribine in hairy cell leukemia: a SAKK trialRudolf Benz, Kornelius Arn, Martin Andres, et al.
Hematological Oncology|December 7, 2023
Hematopoietic cell transplantation and cellular therapies in Switzerland. Evolution over 25 years. A report from the stem cell transplantation and cellular therapies working groups of the SBST 1997-2021Jakob R Passweg, Helen Baldomero, Marc Ansari, et al.
Blood Advances|May 10, 2022
SAKK 35/15: a phase 1 trial of obinutuzumab in combination with venetoclax in patients with previously untreated follicular lymphomaAnastasios Stathis, Ulrich Mey, Sämi Schär, et al.
Cancer|September 25, 2014
Prognostic factors for advanced-stage human immunodeficiency virus-associated classical Hodgkin lymphoma treated with doxorubicin, bleomycin, vinblastine, and dacarbazine plus combined antiretroviral therapy: a multi-institutional retrospective studyJorge J Castillo, Mark Bower, Jérémy Brühlmann, et al.
Blood Advances|March 4, 2026
OUTCOMES OF PATIENTS OVER 70 YEARS TREATED WITH BREXU-CEL FOR R/R MANTLE CELL LYMPHOMA: A STUDY FROM THE CTIWP OF EBMTNicole Santoro, Jarl Eduard Mooyaart, Urban Novak, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 27, 2023
Differential Efficacy From the Addition of Bortezomib to R-CHOP in Diffuse Large B-Cell Lymphoma According to the Molecular Subgroup in the REMoDL-B Study With a 5-Year Follow-UpAndrew J Davies, Sharon Barrans, Louise Stanton, et al.
Blood Advances|January 30, 2025
Six-month rituximab-lenalidomide regimen in advanced untreated follicular lymphoma: SAKK 35/10 trial 10-year updateEva Kimby, Sämi Schär, Maria Cristina Pirosa, et al.
Blood Advances|March 25, 2026
Real-world experience with Tabelecleucel within and beyond the approval labelKiavasch Mohammad Nejad Farid, Florian Kocher, Tobias Arnold, et al.
Pageof 11